Max Rosett's most recent trade in Immunome Inc was a trade of 63,656 Common Stock done at an average price of $21.9 . Disclosure was reported to the exchange on April 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Immunome Inc | Max Rosett | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.91 per share. | 02 Apr 2026 | 63,656 | 55,381 | - | 21.9 | 1,394,703 | Common Stock |
| Immunome Inc | Max Rosett | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. | 02 Apr 2026 | 39,713 | 119,037 | - | 1.4 | 53,613 | Common Stock |
| Immunome Inc | Max Rosett | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2026 | 39,713 | 0 | - | - | Stock option (right to buy) | |
| Immunome Inc | Max Rosett | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.05 per share. | 02 Apr 2026 | 31,848 | 79,324 | - | 1.0 | 33,440 | Common Stock |
| Immunome Inc | Max Rosett | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2026 | 31,848 | 60,000 | - | - | Stock option (right to buy) | |
| Immunome Inc | Max Rosett | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 22.48 per share. | 02 Apr 2026 | 1,344 | 54,037 | - | 22.5 | 30,213 | Common Stock |
| Immunome Inc | Max Rosett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2025 | 207,000 | 207,000 | - | - | Employee Stock Option (right to buy) | |
| Immunome Inc | Max Rosett | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.05 per share. | 19 Sep 2024 | 42,000 | 61,856 | - | 1.1 | 44,100 | Common Stock |
| Immunome Inc | Max Rosett | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Sep 2024 | 42,000 | 91,848 | - | - | Stock option (right to buy) | |
| Immunome Inc | Max Rosett | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.01 per share. | 19 Sep 2024 | 14,380 | 47,476 | - | 16.0 | 230,224 | Common Stock |
| Immunome Inc | Max Rosett | EVP, Operations & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2024 | 190,000 | 190,000 | - | - | Stock option (right to buy) | |
| Immunome Inc | Max Rosett | EVP, Operations & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 30,000 | 30,000 | - | - | Stock option (right to buy) | |
| Immunome Inc | Rosett Max | EVP, OPERATIONS & INTERIM CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 175,000 | 175,000 | - | - | Stock option (right to buy) |